Cephalalgia · 1988 · 13 citations · 8 references
MedicinePharmacologyDrug MetabolismNeurochemistryNeuropharmacologyCytochrome P450 EnzymesCytochrome P450-mediated MetabolismHepatic Drug MetabolismHepatic ImpairmentCytochrome P450 BiomarkersCytochrome P450 Drug MetabolismCytochrome P450 Enzyme ActivityCytochrome P450 Metabolic PathwaysCytochrome P450 PathwaysHydroxylationMigraine AssociationOxidation
Hepatic cytochrome P450-dependent oxidation is deficient in 5% to 10% of the Caucasian population. A similar percentage seems to suffer from migraine. The hypothesis was tested that an oxidation deficiency possibly relevant to potential dietary triggers plays a role in the pathogenesis of migraine. In 37 migraine sufferers and 26 controls age- and sex-matched to 26 of these patients, debrisoquine hydroxylation following an oral dose of 10 mg was employed as a marker of oxidation status, determined by calculating the metabolic ratio (MR): urinary debrisoquine/urinary 4-hydroxydebrisoquine. MR was similarly distributed in migraineurs and controls. Three subjects in each group were poor metabolizers (MR greater than 30, versus normal range, 0.1-12). MR in patients did not depend on type of migraine (common versus classic), attack frequency, the presence of trigger factors, smoking or a history of adverse reactions or sensitivity to medicines.
8
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
A. Mahgoub, L. G. Dring, Jeffrey R. Idle et al. · The Lancet · 1977 · 1.2K citations
ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINE
André Barbeau, Madeleine Roy, S. Paris et al. · The Lancet · 1985 · 230 citations
PLATELET PHENOLSULPHOTRANSFERASE DEFICIENCY IN DIETARY MIGRAINE
Julia Littlewood, Vivette Glover, Merton Sandler et al. · The Lancet · 1982 · 93 citations
Polymorphic drug oxidation in humans.
Michel Eichelbaum · PubMed · 1984 · 62 citations
Medicine, Genetics, Pharmacology +15